<u>Listing of Claims</u>:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Original) An antineoplastic composition comprising an antineoplastic-effective amount of a methylol transfer agent (MTA) in combination with a biodegradable adhesive capable of adhering to tissue of a living subject.
- 2. (Original) The composition of claim 1 wherein said MTA is taurolidine, taurultam or a mixture thereof, said composition initially is in a fluid or semi-fluid state with said MTA at a concentration within a range of about 0.5-80% by weight, and after said adhering to said tissue, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.
- 3. (Original) The composition of claim 1 wherein said composition initially is in a liquid, semi-liquid or suspension state, said MTA is taurolidine, taurultam or a mixture thereof, and is at a concentration within a range of about 0.1-160mg/ml, and after said adhering to said tissue, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.
- 4. (Original) The composition of claim 3 wherein said adhesive comprises a fibrin sealant matrix.

- 5. (Original) The composition of claim 4 wherein said concentration is about 20-100mg/ml.
- 6. (Original) The composition of claim 5 wherein said concentration is about 50-80mg/ml.
- 7. (Withdrawn) A method of treatment for preventing or inhibiting growth of cancer cells, comprising applying the antineoplastic composition of claim 1 to tissue of a living subject in need of said treatment.
- 8. (Withdrawn) The method of claim 7 wherein said MTA is taurolidine, taurultam or a mixture thereof, said composition is applied to said tissue in a fluid or semi-fluid state with said MTA at a concentration within a range of about 0.5-80% by weight, and after said composition is applied, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.
- 9. (Withdrawn) The method of claim 7 wherein said state is a liquid, semi-liquid or suspension state, said MTA is taurolidine, taurultam or a mixture thereof, and is at a concentration within a range of about 0.1-160mg/ml, and after said composition is applied, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.

- 10. (Withdrawn) The method of claim 9 wherein said adhesive comprises a fibrin sealant matrix.
- 11. (Withdrawn) The method of claim 10 wherein said concentration is about 20-100mg/ml.
- 12. (Withdrawn) The method of claim 5 wherein said concentration is about 50-80mg/ml.
- 13. (Withdrawn) The method of claim 7 wherein prior to said applying, a tumor is removed from an area of said tissue.
- 14. (Withdrawn) The method of claim 13 wherein said composition is applied to said area in a layer.
- 15. (Withdrawn) The method of claim 14 wherein said layer has a thickness of about 0.1-10mm.
- 16. (Withdrawn) The method of claim 15 wherein said layer has a thickness of about 1-5mm.

- 17. (Withdrawn) The method of claim 16 wherein said layer has a thickness of about 1.5-2.5mm.
- 18. (Withdrawn) The method of claim 14 wherein said layer is applied by spraying said composition onto said area.
- 19. (Withdrawn) The method of claim 14 wherein, after application of said layer, said layer is covered and sealed with a sealing second layer which does not contain said MTA.
- 20. (Previously presented) The composition of claim 1 wherein said MTA is taurolidine, taurultam or a mixture thereof.
- 21. (Withdrawn) The method of claim 7 wherein said MTA is taurolidine, taurultam or a mixture thereof.
- 22. (Withdrawn) The method of claim 7 further comprising intravenous administration of said MTA to said subject.
- 23. (Withdrawn) The method of claim 22 wherein said MTA is taurolidine, taurultam or a mixture thereof.

- 24. (Previously presented) A system for preventing or inhibiting growth of cancer cells in a subject, comprising the antineoplastic composition of claim 1, in combination with an intravenously administrable MTA for intravenous administration to said subject.
- 25. (Previously presented) The system of claim 24 wherein said MTA is taurolidine, taurultam or a mixture thereof.